NVET News

Ten deals were on the IPO calendar to price this past week, but only three made it through as seven health care IPOs delayed going public. The year's first energy IPO was also the first to raise over $1 billion as natural gas MLP Columbia Pipeline Partners priced above its range and...read more

Nexvet Biopharma, which is developing biologics for the treatment of pain and inflammation in cats and dogs, raised $40 million by offering 4.0 million shares at $10.00, well below the $13 to $16 range. Nexvet Biopharma will list on the NASDAQ under the symbol NVET. BofA Merrill Lynch and Cowen & Company acted as joint bookrunners on the deal....read more

Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight IPOs are in the health care sector and...read more

Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, announced terms for its IPO on Monday. The Dublin, Ireland-based company plans to raise $58 million by offering 4.0 million shares at a price range of $13 to $16. At the midpoint of the proposed range, Nexvet would command a fully diluted market value of $179 million. A number of...read more